The latest announcement is out from AstraZeneca ( (GB:AZN) ).
AstraZeneca, in collaboration with Daiichi Sankyo, announced that their drug Enhertu has been recommended for approval in the EU for treating patients with HER2-low or HER2-ultralow metastatic breast cancer, based on the DESTINY-Breast06 Phase III trial results. This recommendation by the Committee for Medicinal Products for Human Use (CHMP) marks a significant advancement in breast cancer treatment, offering a new HER2-directed therapy option for patients who have progressed on endocrine therapy, potentially improving outcomes and shifting current treatment paradigms.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in oncology, cardiovascular, renal & metabolism, and respiratory & immunology. The company is known for its innovative approach in the pharmaceutical industry and has a strong market presence worldwide.
YTD Price Performance: 16.48%
Average Trading Volume: 2,662,628
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: £186.3B
See more insights into AZN stock on TipRanks’ Stock Analysis page.